Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options

Drug Healthc Patient Saf. 2010:2:49-59. doi: 10.2147/dhps.s7197. Epub 2010 May 20.

Abstract

An excess amount of glucocorticoids represents the primary and most frequent etiological factor influencing secondary osteoporosis. Patients receiving glucocorticoids, but also those with the endogenous form of hypercorticism, are at high risk for the loss of bone density, with the subsequent occurrence of pathological fractures. In this review, we summarize the currently available methods of prevention and the treatment of glucocorticoid-induced osteoporosis. We also include a proposal for both a prophylactic and therapeutic approach that takes into account the risk factors typical for long-term users of glucocorticoids.

Keywords: bisphosphonates; bone mineral density; calcium and vitamin D; glucocorticoid-induced osteoporosis; osteoporotic fractures; teriparatide.